AbCellera Biologics Inc.

NasdaqGS:ABCL 주식 보고서

시가총액: US$864.5m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AbCellera Biologics 관리

관리 기준 확인 4/4

AbCellera Biologics' CEO는 Carl Hansen, Nov2012 에 임명되었습니다 의 임기는 11.58 년입니다. 총 연간 보상은 $ 714.94K, 64.3% 로 구성됩니다. 64.3% 급여 및 35.7% 보너스(회사 주식 및 옵션 포함). 는 $ 170.90M 가치에 해당하는 회사 주식의 19.24% 직접 소유합니다. 170.90M. 경영진과 이사회의 평균 재임 기간은 각각 2.9 년과 4.8 년입니다.

주요 정보

Carl Hansen

최고 경영자

US$714.9k

총 보상

CEO 급여 비율64.3%
CEO 임기11.6yrs
CEO 소유권19.2%
경영진 평균 재임 기간2.9yrs
이사회 평균 재임 기간4.8yrs

최근 관리 업데이트

Recent updates

Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

May 29
Companies Like AbCellera Biologics (NASDAQ:ABCL) Are In A Position To Invest In Growth

AbCellera: Cash Providing Shelter From Market Weakness

May 16

AbCellera: Victim Of Its Own Success

Feb 28

AbCellera Biologics: Continuing To Expand Partnerships

Feb 13

Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

Feb 04
Is Now The Time To Put AbCellera Biologics (NASDAQ:ABCL) On Your Watchlist?

AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

Nov 29
AbCellera Biologics Inc. (NASDAQ:ABCL) Shares Could Be 31% Below Their Intrinsic Value Estimate

AbCellera Biologics: Many Reasons To Own This Undervalued Stock

Sep 06

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

Aug 14

AbCellera partnering with Atlas Ventures on development of therapeutic antibodies

Aug 03

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

Jun 06

Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

May 13
Need To Know: Analysts Are Much More Bullish On AbCellera Biologics Inc. (NASDAQ:ABCL)

Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

May 07
Not Many Are Piling Into AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Yet As It Plummets 25%

AbCellera Biologics: Potentially Bottoming Out Amidst Terrible Market Sentiment

Apr 22

AbCellera Biologics: Bebtelovimab Supply Deal Provides A Much Needed Shot In The Arm

Feb 11

AbCellera Biologics: Potentially Worth Over $41 Currently, Without COVID Revenues

Dec 05

AbCellera Biologics: The COVID Premium Is Gone, Thanks To Merck - Time To Buy

Oct 18

AbCellera Biologics: I Was Wrong

Aug 20

AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Are More Bearish Than They Used To Be

Aug 17
AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Are More Bearish Than They Used To Be

AbCellera Biologics: A Buy At Current Prices

Aug 06

CEO 보상 분석

Carl Hansen 의 보수는 AbCellera Biologics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$147m

Dec 31 2023US$715kUS$460k

-US$146m

Sep 30 2023n/an/a

-US$129m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$50m

Dec 31 2022US$9mUS$450k

US$159m

Sep 30 2022n/an/a

US$248m

Jun 30 2022n/an/a

US$200m

Mar 31 2022n/an/a

US$205m

Dec 31 2021US$9mUS$400k

US$153m

Sep 30 2021n/an/a

US$177m

Jun 30 2021n/an/a

US$197m

Mar 31 2021n/an/a

US$203m

Dec 31 2020US$17mUS$296k

US$85m

Sep 30 2020n/an/a

-US$285k

Jun 30 2020n/an/a

US$2m

Mar 31 2020n/an/a

-US$3m

Dec 31 2019US$250kUS$177k

-US$2m

보상 대 시장: Carl 의 총 보상 ($USD 714.94K ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 3.43M ).

보상과 수익: Carl 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Carl Hansen (49 yo)

11.6yrs

테뉴어

US$714,939

보상

Dr. Carl L. G. Hansen, Ph.D. is a Co-Founder of AbCellera Biologics Inc. and has been its Chief Executive Officer and Director since November 2012 and serves as its Chairperson. Dr. Hansen serves as a Memb...

리더십 팀

이름위치테뉴어보상소유권
Carl Hansen
CEO, President & Chairperson11.6yrsUS$714.94k19.24%
$ 166.4m
Andrew Booth
Chief Financial Officer4.8yrsUS$674.56k0.097%
$ 834.9k
Veronique Lecault
COO & Director5.4yrsUS$650.59k3.24%
$ 28.0m
Tryn Stimart
Chief Legal Officer4.8yrsUS$667.69k0.00017%
$ 1.5k
Marcie Thiessen
Senior Director of Finance & Accountingno data데이터 없음데이터 없음
Ester Falconer
Chief Technology Officer3.4yrs데이터 없음데이터 없음
Kathleen Reid
Head of Corporate Communicationsless than a year데이터 없음데이터 없음
Graham Craig
Director of Corporate Development1.4yrs데이터 없음데이터 없음
Murray McCutcheon
Senior Vice President of Partnering1.4yrs데이터 없음데이터 없음
Neil Aubuchon
Chief Commercial Officer2.4yrsUS$5.61m0.016%
$ 142.3k
Adam Clarke
Senior Vice President of Discoveryno data데이터 없음데이터 없음
Paul Colussi
Site Head & VP of Complex Membrane Protein Technologies1.4yrs데이터 없음데이터 없음

2.9yrs

평균 재임 기간

49.5yo

평균 연령

경험이 풍부한 관리: ABCL 의 관리팀은 경험 ( 2.9 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Carl Hansen
CEO, President & Chairperson11.6yrsUS$714.94k19.24%
$ 166.4m
Veronique Lecault
COO & Director5.8yrsUS$650.59k3.24%
$ 28.0m
Michael Hayden
Independent Lead Director4.8yrsUS$105.00k0.49%
$ 4.2m
John Montalbano
Independent Non-Employee Director3.6yrsUS$77.50k0.031%
$ 267.6k
Wen-Chaun Lo
Independent Director2.5yrsUS$55.00k0%
$ 0

4.8yrs

평균 재임 기간

58yo

평균 연령

경험이 풍부한 이사회: ABCL 의 이사회는 경험(평균 재직 기간 4.8 년)으로 간주됩니다.